Team:SupBiotech-Paris/Bibliography
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
(→Ethics) |
||
(11 intermediate revisions not shown) | |||
Line 8: | Line 8: | ||
</a></div> | </a></div> | ||
</html> | </html> | ||
+ | == Therapies == | ||
{| | {| | ||
|- style="background: grey; color:white; text-align: center; font-weight:bold; " | |- style="background: grey; color:white; text-align: center; font-weight:bold; " | ||
- | |width=120px height=40px| | + | |width=120px height=40px|Chapter |
|width=40px|Ref. | |width=40px|Ref. | ||
- | |width=120px| | + | |width=120px|Authors |
- | |width=560px| | + | |width=560px|Title |
- | |width=70px| | + | |width=70px|Year |
|- style="background: white; text-align: center;" | |- style="background: white; text-align: center;" | ||
Line 50: | Line 51: | ||
|http://www.genetics.com.au/index.asp | |http://www.genetics.com.au/index.asp | ||
|XXXX | |XXXX | ||
+ | |} | ||
+ | |||
+ | |||
+ | <span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span> | ||
+ | |||
+ | == Vectorization == | ||
+ | {| | ||
+ | |- style="background: grey; color:white; text-align: center; font-weight:bold; " | ||
+ | |width=120px height=40px|Chapter | ||
+ | |width=40px|Ref. | ||
+ | |width=120px|Authors | ||
+ | |width=560px|Title | ||
+ | |width=70px|Year | ||
|- style="background: #C0C0C0; text-align: center;" | |- style="background: #C0C0C0; text-align: center;" | ||
Line 183: | Line 197: | ||
|Nanotoxicology and nanomedicine: making hard decisions | |Nanotoxicology and nanomedicine: making hard decisions | ||
|2008 | |2008 | ||
+ | |} | ||
+ | |||
+ | |||
+ | <span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span> | ||
+ | |||
+ | == Tissue Vector == | ||
+ | {| | ||
+ | |- style="background: grey; color:white; text-align: center; font-weight:bold; " | ||
+ | |width=120px height=40px|Chapter | ||
+ | |width=40px|Ref. | ||
+ | |width=120px|Authors | ||
+ | |width=560px|Title | ||
+ | |width=70px|Year | ||
|- style="background: white; text-align: center;" | |- style="background: white; text-align: center;" | ||
Line 233: | Line 260: | ||
|The thymus as a target for mycobacterial infections | |The thymus as a target for mycobacterial infections | ||
|2007 | |2007 | ||
+ | |} | ||
+ | |||
+ | |||
+ | <span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span> | ||
+ | |||
+ | == Cell Vector == | ||
+ | {| | ||
+ | |- style="background: grey; color:white; text-align: center; font-weight:bold; " | ||
+ | |width=120px height=40px|Chapter | ||
+ | |width=40px|Ref. | ||
+ | |width=120px|Authors | ||
+ | |width=560px|Title | ||
+ | |width=70px|Year | ||
|- style="background: #C0C0C0; text-align: center;" | |- style="background: #C0C0C0; text-align: center;" | ||
Line 296: | Line 336: | ||
|Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization | |Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization | ||
|1997 | |1997 | ||
+ | |} | ||
+ | |||
+ | |||
+ | <span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span> | ||
+ | |||
+ | == Therapeutic Plasmide == | ||
+ | {| | ||
+ | |- style="background: grey; color:white; text-align: center; font-weight:bold; " | ||
+ | |width=120px height=40px|Chapter | ||
+ | |width=40px|Ref. | ||
+ | |width=120px|Authors | ||
+ | |width=560px|Title | ||
+ | |width=70px|Year | ||
|- style="background: white; text-align: center;" | |- style="background: white; text-align: center;" | ||
Line 345: | Line 398: | ||
|Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature | |Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature | ||
|2003 | |2003 | ||
+ | |} | ||
+ | |||
+ | |||
+ | <span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span> | ||
+ | |||
+ | == Antitumor action == | ||
+ | {| | ||
+ | |- style="background: grey; color:white; text-align: center; font-weight:bold; " | ||
+ | |width=120px height=40px|Chapitre | ||
+ | |width=40px|Ref. | ||
+ | |width=120px|Auteurs | ||
+ | |width=560px|Titre | ||
+ | |width=70px|Année | ||
+ | |||
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Antitumor action | ||
+ | |[1] | ||
+ | |Chunlin Yang et al | ||
+ | |Adenovirus-mediated Wild-Type p53 Expression Induces Apoptosis and Suppresses Tumorigenesis of Prostatic Tumor Cells | ||
+ | |1995 | ||
|- style="background: #C0C0C0; text-align: center;" | |- style="background: #C0C0C0; text-align: center;" | ||
- | |height=40px| | + | |height=40px|Antitumor action |
- | |[] | + | |[2] |
- | | | + | |Corrado Cirielli et al. |
- | | | + | |Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma |
- | | | + | |1999 |
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Antitumor action | ||
+ | |[3] | ||
+ | |Su-Ping Ren et al. | ||
+ | |Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro | ||
+ | |2006 | ||
+ | |||
+ | |- style="background: #C0C0C0; text-align: center;" | ||
+ | |height=40px|Antitumor action | ||
+ | |[4] | ||
+ | |Zhao-hua Qiu et al | ||
+ | |Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes | ||
+ | |2002 | ||
+ | |||
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Antitumor action | ||
+ | |[5] | ||
+ | |Zhao-hua Qiu et al. | ||
+ | |Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells | ||
+ | |2001 | ||
+ | |||
+ | |- style="background: #C0C0C0; text-align: center;" | ||
+ | |height=40px|Antitumor action | ||
+ | |[6] | ||
+ | |Markus Reiser et al. | ||
+ | |Induction of cell proliferation arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene | ||
+ | |2000 | ||
+ | |||
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Antitumor action | ||
+ | |[7] | ||
+ | |Louis L. Pisters et al. | ||
+ | |Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer | ||
+ | |2004 | ||
+ | |||
+ | |- style="background: #C0C0C0; text-align: center;" | ||
+ | |height=40px|Antitumor action | ||
+ | |[8] | ||
+ | |Susan C. Modesitt et al. | ||
+ | |In Vitro and in Vivo Adenovirus-mediated p53 and p16 Tumor Suppressor Therapy in Ovarian Cancer | ||
+ | |2001 | ||
+ | |||
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Antitumor action | ||
+ | |[9] | ||
+ | |Yong-song GUAN et al. | ||
+ | |Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up | ||
+ | |2009 | ||
+ | |} | ||
+ | |||
+ | |||
+ | <span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span> | ||
+ | |||
+ | == Ethics == | ||
+ | {| | ||
+ | |- style="background: grey; color:white; text-align: center; font-weight:bold; " | ||
+ | |width=120px height=40px|Chapter | ||
+ | |width=40px|Ref. | ||
+ | |width=120px|Authors | ||
+ | |width=560px|Title | ||
+ | |width=70px|Year | ||
+ | |||
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Ethics | ||
+ | |[1] | ||
+ | |Joël Rosnay | ||
+ | |Biologie de synthèse: Enjeux et défis pour l’humanité | ||
+ | |2004 | ||
+ | |||
+ | |- style="background: #C0C0C0; text-align: center;" | ||
+ | |height=40px|Ethics | ||
+ | |[2] | ||
+ | |Synbiosafe | ||
+ | |http://www.synbiosafe.eu/forum/ | ||
+ | |2008 | ||
+ | |||
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Ethics | ||
+ | |[3] | ||
+ | |Bernadette Bensaude Vincent, Dorothée Benoit-Browaeys | ||
+ | |Petite typologie de la biologie synthétique et enjeux éthiques | ||
+ | |2009 | ||
+ | |||
+ | |- style="background: #C0C0C0; text-align: center;" | ||
+ | |height=40px|Ethics | ||
+ | |[4] | ||
+ | |Anna Deplazes Æ Markus Huppenbauer | ||
+ | |Synthetic organisms and living machines | ||
+ | |2004 | ||
+ | |||
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Ethics | ||
+ | |[5] | ||
+ | |Schmidt M, Ganguli-Mitra A,and al. | ||
+ | |A priority paper for the societal and ethical aspects of synthetic biology | ||
+ | |2009 | ||
+ | |||
+ | |- style="background: #C0C0C0; text-align: center;" | ||
+ | |height=40px|Ethics | ||
+ | |[6] | ||
+ | |Parens E, Johnston J, Moses J. | ||
+ | |Ethics. Do we need "synthetic bioethics"? | ||
+ | |2009 | ||
+ | |} | ||
+ | |||
+ | |||
+ | |||
+ | <span style="float: right">[[Team:SupBiotech-Paris/Bibliography#drapeau|Back to top]]</span> | ||
+ | |||
+ | |||
+ | <html> | ||
+ | <div style="float: right; margin-right: -85px;"> | ||
+ | <a href="https://2009.igem.org/Team:SupBiotech-Paris/Ethic#drapeau" target="_self"> | ||
+ | <img title="Let's go to the next page !" style="width: 100px;" src="https://static.igem.org/mediawiki/2009/e/e9/Suivant.png";> | ||
+ | </a></div> | ||
+ | </html> | ||
+ | |||
+ | == Safety == | ||
+ | {| | ||
+ | |- style="background: grey; color:white; text-align: center; font-weight:bold; " | ||
+ | |width=120px height=40px|Chapter | ||
+ | |width=40px|Ref. | ||
+ | |width=120px|Authors | ||
+ | |width=560px|Title | ||
+ | |width=70px|Year | ||
+ | |||
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Safety | ||
+ | |[1] | ||
+ | |Jonathan B. Tucker and al. | ||
+ | |The Promise and Perils of Synthetic Biology | ||
+ | |2006 | ||
+ | |||
+ | |- style="background: #C0C0C0; text-align: center;" | ||
+ | |height=40px|Safety | ||
+ | |[2] | ||
+ | |Synbiosafe | ||
+ | |http://www.synbiosafe.eu/forum/ | ||
+ | |2008 | ||
+ | |||
+ | |- style="background: white; text-align: center;" | ||
+ | |height=40px|Safety | ||
+ | |[3] | ||
+ | |Vivagora | ||
+ | |http://www.vivagora.org/IMG/pdf/CR-biosynth011009.pdf | ||
+ | |2009 | ||
+ | |||
+ | |- style="background: #C0C0C0; text-align: center;" | ||
+ | |height=40px|Safety | ||
+ | |[4] | ||
+ | |New Atlantis | ||
+ | |http://www.thenewatlantis.com/publications/life-from-scratch | ||
+ | |2004 | ||
|} | |} | ||
Latest revision as of 01:53, 22 October 2009
Contents |
Therapies
Chapter | Ref. | Authors | Title | Year |
Current Therapies | [1] | Lechat P. | Pharmacology | 2006 |
Current Therapies | [2] | Bruguerolle B. | Biological rhythms and medications: a source of variability often neglected in pharmacology | 2008 |
Current Therapies | [1] | Kevin J. Scanlon and al. | Cancer Gene Therapy: Challenges and Opportunities | 2004 |
Gene Therapies | [2] | Gouze JN and al. | A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer | 2003 |
Gene Therapies | [3] | Centre for Genetics Education | http://www.genetics.com.au/index.asp | XXXX |
Vectorization
Chapter | Ref. | Authors | Title | Year |
Vectorization | [1] | Couvreur P. | L'encapsulation de médicament | 2003 |
Vectorization | [2] | Andrieux K. and al. | Nanotechnology and new drug | 2003 |
Vectorization | [3] | Torchilin V.P. | Recent Approaches to Intracellular Delivery of Drugs and DNA and Organelle Targeting | 2006 |
Vectorization | [4] | Davis M.E. and al. | Nanoparticle therapeutics: an emerging treatment modality for cancer | 2008 |
Vectorization | [5] | Seow Y. and al. | Biological Gene Delivery Vehicles: Beyond Viral Vectors | 2009 |
Vectorization | [6] | Decroly E. | Vectorology | 2005 |
Vectorization | [7] | Robbins P.D. and al. | Viral Vectors for Gene Therapy | 1998 |
Vectorization | [8] | Wei M.Q. and al. | Bacterial targeted tumour therapy-dawn of a new era | 2008 |
Vectorization | [9] | Ryan R.M. and al. | Use of bacteria in anti-cancer therapies | 2005 |
Vectorization | [10] | Mehnert | Solid lipid nanoparticles: Production, characterization and applications | 2001 |
Vectorization | [11] | Lasic D.D. | Liposomes in gene therapy | 1996 |
Vectorization | [12] | Lutten J. and al. | Biodegradable polymers as non-viral carriers for plasmid DNA delivery | 2008 |
Vectorization | [13] | Jiskoot W. and al. | Immunological Risk of Injectable Drug Delivery Systems | 2009 |
Vectorization | [14] | Head M. and al. | Mechanism and computer simulation of immune complex formation, opsonization, and clearance | 1996 |
Vectorization | [15] | Koide H. and al. | Particle size-dependent triggering of accelerated blood clearance phenomenon | 2008 |
Vectorization | [16] | Ishida T. and al. | Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes | 2005 |
Vectorization | [17] | Wang XY and al. | Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes | 2007 |
Vectorization | [18] | Tosi M.F. and al. | Innate immune responses to infection | 2005 |
Vectorization | [19] | Linkov I and al. | Nanotoxicology and nanomedicine: making hard decisions | 2008 |
Tissue Vector
Chapter | Ref. | Authors | Title | Year |
Tissue Vector | [1] | Ronald S. and al. | Antimicrobial mechanisms of phagocytes and bacterial evasion strategies | 2009 |
Tissue Vector | [2] | Clark B. Inderlied and al. | The Mycobacterium avium Complex | 1993 |
Tissue Vector | [3] | Nisheeth Agarwal and al. | Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase | 2009 |
Tissue Vector | [4] | Hunter R.L. and al. | Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs | 2007 |
Tissue Vector | [5] | Axelrod S and al. | Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide | 2008 |
Tissue Vector | [6] | Nicole N van der Wel and al. | Subcellular localization of mycobacteria in tissues and detection of lipid antigens in organelles using cryo-techniques for light and electron microscopy | 2005 |
Tissue Vector | [7] | Claudia Nobrega and al. | The thymus as a target for mycobacterial infections | 2007 |
Cell Vector
Chapter | Ref. | Authors | Title | Year |
Cell Vector | [1] | Harrison Echols and al. | Genetic Map of Bacteriophage Lambda | 1978 |
Cell Vector | [2] | Joseph Sambrook and al. | Molecular Cloning: A Laboratory Manual (Third Edition) | 2001 |
Cell Vector | [3] | Court DL and al. | A New Look at Bacteriophage lambda Genetic Networks | 2007 |
Cell Vector | [4] | Ortega ME and al. | Bacteriophage Lambda gpNu1 and Escherichia coli IHF Proteins Cooperatively Bind and Bend Viral DNA: Implications for the Assembly of a Genome-Packaging Motor | 2006 |
Cell Vector | [5] | Feiss M. and al. | Bactériophage Lambda Terminase and the Mechanism of Viral DNA Packaging | 2005 |
Cell Vector | [6] | Hang JQ and al. | The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB | 2001 |
Cell Vector | [7] | Becker A and al. | Bacteriophage lambda DNA : The begginning of the End | 1990 |
Cell Vector | [8] | Hochschild A and al. | The bactériophage lambda cI protein finds an asymmetric solution | 2009 |
Cell Vector | [9] | Phoebe L.Stewart1 and al. | Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization | 1997 |
Therapeutic Plasmide
Chapter | Ref. | Authors | Title | Year |
Therapeutic Plasmide | [1] | Ortega ME et al. | Bacteriophage lambda gpNu1 and Escherichia coli IHF proteins cooperatively bind and bend viral DNA: implications for the assembly of a genome-packaging motor | 2006 |
Therapeutic Plasmide | [2] | Joseph Sambrook and al. | Molecular Cloning: A Laboratory Manual (Third Edition) | 2001 |
Therapeutic Plasmide | [3] | Court DL and al. | A New Look at Bacteriophage lambda Genetic Networks | 2007 |
Therapeutic Plasmide | [4] | Feiss M. and al. | Viral Genome Packaging Machines: Genetics, Structure and Mechanism | 2005 |
Therapeutic Plasmide | [5] | Hang JQ and al. | The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB | 2001 |
Therapeutic Plasmide | [6] | Becker A and al. | Bacteriophage lambda DNA : The begginning of the End | 1990 |
Therapeutic Plasmide | [7] | Young et al. | Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature | 2003 |
Antitumor action
Chapitre | Ref. | Auteurs | Titre | Année |
Antitumor action | [1] | Chunlin Yang et al | Adenovirus-mediated Wild-Type p53 Expression Induces Apoptosis and Suppresses Tumorigenesis of Prostatic Tumor Cells | 1995 |
Antitumor action | [2] | Corrado Cirielli et al. | Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma | 1999 |
Antitumor action | [3] | Su-Ping Ren et al. | Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro | 2006 |
Antitumor action | [4] | Zhao-hua Qiu et al | Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes | 2002 |
Antitumor action | [5] | Zhao-hua Qiu et al. | Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells | 2001 |
Antitumor action | [6] | Markus Reiser et al. | Induction of cell proliferation arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene | 2000 |
Antitumor action | [7] | Louis L. Pisters et al. | Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer | 2004 |
Antitumor action | [8] | Susan C. Modesitt et al. | In Vitro and in Vivo Adenovirus-mediated p53 and p16 Tumor Suppressor Therapy in Ovarian Cancer | 2001 |
Antitumor action | [9] | Yong-song GUAN et al. | Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up | 2009 |
Ethics
Chapter | Ref. | Authors | Title | Year |
Ethics | [1] | Joël Rosnay | Biologie de synthèse: Enjeux et défis pour l’humanité | 2004 |
Ethics | [2] | Synbiosafe | http://www.synbiosafe.eu/forum/ | 2008 |
Ethics | [3] | Bernadette Bensaude Vincent, Dorothée Benoit-Browaeys | Petite typologie de la biologie synthétique et enjeux éthiques | 2009 |
Ethics | [4] | Anna Deplazes Æ Markus Huppenbauer | Synthetic organisms and living machines | 2004 |
Ethics | [5] | Schmidt M, Ganguli-Mitra A,and al. | A priority paper for the societal and ethical aspects of synthetic biology | 2009 |
Ethics | [6] | Parens E, Johnston J, Moses J. | Ethics. Do we need "synthetic bioethics"? | 2009 |
Safety
Chapter | Ref. | Authors | Title | Year |
Safety | [1] | Jonathan B. Tucker and al. | The Promise and Perils of Synthetic Biology | 2006 |
Safety | [2] | Synbiosafe | http://www.synbiosafe.eu/forum/ | 2008 |
Safety | [3] | Vivagora | http://www.vivagora.org/IMG/pdf/CR-biosynth011009.pdf | 2009 |
Safety | [4] | New Atlantis | http://www.thenewatlantis.com/publications/life-from-scratch | 2004 |